poisar

Stocks · News reference

UBS Downgrades Chemours to Neutral, Lowers Price Target to $18

BenzingaAug 10, 2026, 11:29 AMBenzinga Newsdesk

UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 10, 2026, 11:29 AM
Checked
Aug 10, 2026, 11:29 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 27, 2026, 10:56 AMResearchandmarkets.Com

    High Performance Fluoropolymers Market Forecast 2026-2032 | Semiconductor, Electric Vehicle and Battery Demand Accelerates High Performance Fluoropolymers Market Growth

    The global high-performance fluoropolymers market is projected to grow from USD 5.17 billion in 2026 to USD 7.82 billion by 2032 at a CAGR of 7.11%, driven by semiconductor fabrication, electric vehicle electrification, battery technology, and hydrogen infrastructure demands. Key growth factors include regulatory compliance requirements, AI-driven innovation in materials discovery, and expanding applications across aerospace, medical devices, and industrial coatings.

    Read original at globenewswire-inc